- Care is now structured by organ involvement.
- Earlier biologic use is recommended for major organ disease.
- Colchicine remains first-line for mucocutaneous and joint symptoms.
- Tumur necrosis factor inhibitors are favored for severe or refractory disease.
- Evidence is limited; key gaps remain in long-term management.
Source: Annals of the Rheumatic Diseases
